Neurizon Begins Pivotal NUZ-001 Dosing in HEALEY ALS Platform Trial

Pharmaust Limited ( (AU:NUZ) ) just unveiled an update.

Neurizon Therapeutics has begun dosing the first participant with its lead candidate NUZ-001 in Regimen I of the HEALEY ALS Platform Trial, a multicentre adaptive Phase 2/3 study run by the Sean M. Healey & AMG Center for ALS at Mass General Brigham. The trial will enrol about 160 ALS patients across more than 70 U.S. sites in a 36-week randomised, double-blind, placebo-controlled design to evaluate NUZ-001’s impact on disease progression and safety.

Entry into the highly competitive HEALEY platform gives Neurizon access to an established clinical framework, top-tier ALS investigators and streamlined infrastructure, positioning this study as the company’s potential registrational trial to support future regulatory submissions. The move follows a small Phase 1 program that showed encouraging preliminary efficacy and a favourable safety profile, marking a significant milestone in Neurizon’s bid to advance NUZ-001 as a new therapy option in a disease area with high unmet need.

The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.

More about Pharmaust Limited

Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative diseases, with a particular emphasis on amyotrophic lateral sclerosis (ALS). Listed on the ASX and OTCQB, the company is advancing its lead candidate NUZ-001 through late-stage clinical development in collaboration with leading ALS centres in the United States.

Average Trading Volume: 536,093

Technical Sentiment Signal: Sell

Current Market Cap: A$66.8M

See more data about NUZ stock on TipRanks’ Stock Analysis page.